MedpaceMEDP
About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Employees: 5,900
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 7 (+1) [Q1 2025]
1.19% more ownership
Funds ownership: 81.53% [Q4 2024] → 82.72% (+1.19%) [Q1 2025]
8% more repeat investments, than reductions
Existing positions increased: 227 | Existing positions reduced: 211
0% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 67
1% less funds holding
Funds holding: 581 [Q4 2024] → 573 (-8) [Q1 2025]
9% less capital invested
Capital invested by funds: $8.42B [Q4 2024] → $7.67B (-$745M) [Q1 2025]
34% less call options, than puts
Call options by funds: $14.5M | Put options by funds: $22M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Barclays Luke Sergott | 7%downside $300 | Equal-Weight Initiated | 24 Jun 2025 |
Truist Securities Jailendra Singh | 7%downside $300 | Hold Maintained | 23 Apr 2025 |
Baird Eric Coldwell | 3%downside $313 | Neutral Maintained | 23 Apr 2025 |
TD Cowen Charles Rhyee | 1%upside $328 | Hold Downgraded | 14 Apr 2025 |
Financial journalist opinion
Based on 5 articles about MEDP published over the past 30 days
